UnitedHealth Group Stock Awaits Q3 Earnings Test on Cost Trends

UnitedHealth Group (UNH) is facing a critical earnings test on October 13, 2026, when it will release its third-quarter results before the market opens. The stock was trading at USD 374.98 on October 6, 2026, down 0.95 percent from the prior close. Investors are closely watching the report to gauge the company's cost trends and earnings recovery.

The second quarter of 2026 saw UnitedHealth deliver adjusted earnings per share (EPS) of USD 6.38, significantly higher than the USD 4.94 consensus and USD 4.08 from the prior-year quarter. Revenue reached USD 112.03 billion, up 0.4 percent year over year and above the USD 110.81 billion consensus. The strong profitability was driven more by cost management than sales growth, with the medical care ratio improving to 86.7 percent from 89.4 percent in the prior-year quarter.

Medical costs remain a decisive factor for the upcoming report. Management has projected a full-year adjusted EPS range of USD 19.50-20.00 and a 2026 medical care ratio of 88.1 percent plus or minus 25 basis points. Additionally, UnitedHealthcare plans to narrow its coverage strategy, providing 66 percent of members access to both HMO and PPO plans in 2027, down from 70 percent in 2026, to prioritize plan economics amid elevated medical utilization.

As of October 6, 2026, UnitedHealth's stock price was 18.8 percent below its 52-week high of USD 461.62 and above the 52-week low of USD 255.97. The market capitalization stood at USD 340.5 billion. Analysts have rated the stock predominantly as a Buy, with an average price target of USD 465.75, which is 24.2 percent above the current price. The upcoming earnings report will be crucial in determining whether improved medical costs can support the recovery implied by the consensus.